青光眼患者对前列腺素类似物的依从性与持续性:系统综述与Meta分析
第1年依从患者平均比例为44%(95%CI 31%-58%),平均MPR/PDC第1年为54%(95%CI 38%-75%)、第2年为60%(95%CI 39%-94%);持续用药患者比例从第6个月75%(95%CI 66%-85%)降至第3年31%(95%CI 12%-55%)。作者认为PGA依从性与持续性欠佳常见,且随用药时间延长进一步下降。
要点
- 第1年依从患者平均比例为44%(95%CI 31%-58%),平均MPR/PDC为54%(95%CI 38%-75%)。
- 持续用药患者比例从第6个月75%(95%CI 66%-85%)降至第3年31%(95%CI 12%-55%)。
- 平均治疗持续时间为315.7天(95%CI 190.0-441.5天)。
核心结论
- PGA依从性与持续性欠佳常见,且随用药时间延长进一步下降。
- 这些发现可能凸显不依赖患者每日使用局部药物的程序性青光眼治疗的价值。
研究设计与样本
- 系统文献综述(SLR)与Meta分析(MA),更新2011年SLR,检索MEDLINE、Embase和Cochrane系统综述数据库(CDSR),并手工检索SLR与MA参考文献。
- 纳入成人青光眼患者使用PGA并报告客观持续性或依从性指标的观察性研究。
- SLR纳入50篇文献、报告47项独特研究、涉及961,000例患者;MA纳入除4项未报告患者年龄分布研究外的所有研究。
主要发现
- 使用任何/未特指PGA的患者第1年依从平均比例为44%(95%CI 31%-58%)。
- 使用任何/未特指PGA的患者平均MPR/PDC第1年为54%(95%CI 38%-75%)、第2年为60%(95%CI 39%-94%)。
- 使用任何/未特指PGA的患者持续用药平均比例从第6个月75%(95%CI 66%-85%)降至第3年31%(95%CI 12%-55%)。
- 持续用药比例第1年56%(95%CI 45%-66%)至第2年53%(95%CI 45%-62%)降幅较小,第2年至第3年降幅较大。
- 平均治疗持续时间为315.7天(95%CI 190.0-441.5天)。
关键数值与推荐
- MPR/PDC值>80%表示依从良好。
- 治疗持续时间定义为从初始治疗处方至治疗中止或换药的时间段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To systematically review, synthesize and quantify studies reporting patterns of adherence and persistence with prostaglandin analogues (PGAs) in order to comprehensively understand real-world treatment behavior among patients with glaucoma who are prescribed PGAs. These data can inform the decision between a glaucoma therapy based on either topical PGA medications or procedural PGA-based intervention. DESIGN: Systematic literature review (SLR) and meta-analysis (MA). METHODS: We updated a 2011 SLR using electronic database searches (MEDLINE, Embase and the Cochrane Database of Systematic Reviews [CDSR]), supplemented by hand searches of SLR and MA bibliographies. We included observational studies conducted in adult glaucoma patients treated with PGAs that reported objective measures of persistence or adherence. In addition to estimated rates of adherence and persistence, adherence among patients on any/unspecified PGA was characterized by mean MPR/PDC (medication possession ratio/proportion of days covered, where values >80% indicate good adherence). Duration of therapy was defined as the time period between initial therapy prescription and time of therapy discontinuation or switch. RESULTS: The SLR included 50 publications reporting on 47 unique studies and involving 961,000 patients. The subsequent MA included all but four studies which did not report the age distribution of patients. The mean proportion of patients on any/unspecified PGA who were adherent at Year 1 was 44% (95% CI: 31%-58%). Among patients on any/unspecified PGA, the mean MPR/PDC was 54% (95% CI: 38%-75%) at Year 1 and 60% at Year 2 (95% CI: 39%-94%). The mean proportion of patients on any/unspecified PGA who were persistent fell from 75% (95% CI: 66%-85%) at Month 6 to 31% (95% CI: 12%-55%) at Year 3, with a smaller decrease observed between Year 1 (56%; 95% CI: 45%-66%) and Year 2 (53%; 95% CI: 45%-62%), and a larger decrease between Years 2 and 3. The mean duration on therapy was 315.7 days (95% CI: 190.0%-441.5 days). CONCLUSIONS: Suboptimal adherence and persistence with PGAs are common, with further decreases as duration lengthens. These findings may underscore the value of procedural glaucoma treatments that do not depend on daily patient engagement with topical medications.
引用
- Baudouin C, Myers JS, Van Tassel SH, et al. Adherence and Persistence on Prostaglandin Analogues for Glaucoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025. PMID: 40113120. doi:10.1016/j.ajo.2025.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。